NY-ESO-1 157-165
SLLMWITQC cancer vaccine epitope
9 Amino Acids · MW: 1111.3
Amino Acids
9
Molecular Weight
1111.3
Half-life
<1 h
Research Score
4.5
Studies
85
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is NY-ESO-1 157-165?
A cancer-testis antigen peptide from NY-ESO-1 that is presented by HLA-A2. It is widely used to drive tumor-specific T-cell responses in vaccine and adoptive-immunotherapy research.
Key Benefits & Mechanisms
tumor-selective targeting
CTL induction
high immunogenicity
Research Summary
NY-ESO-1 peptides are among the most studied cancer-testis antigen epitopes in clinical immunotherapy. They have shown strong immunogenicity and are often explored in multi-epitope vaccines and T-cell-based strategies.
Related Peptides
GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Cancer ResearchNelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchWT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Cancer ResearchSurvivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Cancer Research